Cancer Metabolism Based Therapeutics Market - Targeting cancer metabolism condition represents a potential opportunity to develop novel drugs to treat multiple cancer types

The advent of advanced therapies and the increasing prevalence of cancer around the globe is facilitating the growth of the global cancer metabolism-based therapeutics market. According to the International Agency for Research on Cancer, cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. Targeting cancer metabolism conditions is projected to serve major growth opportunities for rare drugs to treat multiple types of cancer. Changing lifestyle and growing aging population is also contributing to the risk of developing cancer among the population.

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/961

Cancer metabolism therapy is based on the idea that tumors have a different metabolic process from normal or healthy cells. While normal cells secrete glycogen and glucose, cancer cells exhibit a lack of glycogen and glucose as well as increased levels of lactic acid. Cancer patients also have a decreased ability to use oxygen as well as an increased use of fatty acids as fuel. This metabolite imbalance is what underlies most of the complications associated with cancer. Cancer therapies that use various types of biological therapies are used to directly target this metabolic disorder.

Regional assessment reveals that, North America is estimated to gain significant growth in the near future and this is attributed to the increasing FDA approval for commercializing cancer metabolism-based therapeutics. For example, in September 2017, the FDA approved Agios’ and Celgene’s enasidenib for acute myeloid leukemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells. Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydro genase 2 (IDH2). Another instance, in August 2020, Tyme Technologies, Inc. a biotechnology company developing cancer metabolism-based therapies (CMBTs™) announced that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its lead pipeline candidate, SM-88 (racemetyrosine), as a treatment for patients with pancreatic cancer.

Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/961

Key Developments:

In January 2021, Elypta has granted a US patent for its liquid biopsy method as a cancer metabolism therapy

In January 2019, Drugmaker Lupin announced that it is in the process of developing a pipeline of products under its new drug discovery program to treat various diseases like cancer and metabolic disorders

In December 2020, Rafael Pharmaceuticals Inc. provider of cancer metabolism-based therapeutics announced it has initiated a Phase 2 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue

Purchase this Report Here – https://www.coherentmarketinsights.com/insight/buy-now/961

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.